Sankei Chemical Co., Ltd. (FKSE:4995)
Japan · Delayed Price · Currency is JPY 1,400.00
0.00 (0.00%)
At close: Aug 8, 2025
Longboard Pharmaceuticals Income Statement
Financials in millions JPY. Fiscal year is December - November.
Millions JPY. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | May '25 May 31, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 | Nov '20 Nov 30, 2020 | 2016 - 2020 |
Revenue | 6,408 | 6,052 | 5,998 | 7,242 | 7,032 | 6,711 | Upgrade |
Revenue Growth (YoY) | 9.24% | 0.90% | -17.18% | 2.99% | 4.78% | -0.27% | Upgrade |
Cost of Revenue | 4,774 | 4,684 | 4,665 | 5,672 | 5,212 | 5,093 | Upgrade |
Gross Profit | 1,634 | 1,368 | 1,333 | 1,570 | 1,820 | 1,618 | Upgrade |
Selling, General & Admin | 1,130 | 1,099 | 1,111 | 1,119 | 1,131 | 1,150 | Upgrade |
Research & Development | 224 | 224 | 233 | 218 | 183 | 180 | Upgrade |
Other Operating Expenses | - | - | - | - | 113 | 129 | Upgrade |
Operating Expenses | 1,354 | 1,323 | 1,344 | 1,337 | 1,427 | 1,459 | Upgrade |
Operating Income | 280 | 45 | -11 | 233 | 393 | 159 | Upgrade |
Interest Expense | -23 | -21 | -17 | -14 | -13 | -13 | Upgrade |
Interest & Investment Income | 15 | 16 | 14 | 13 | 9 | 9 | Upgrade |
Earnings From Equity Investments | 32 | 66 | 30 | 31 | 40 | 28 | Upgrade |
Other Non Operating Income (Expenses) | 18 | 31 | 21 | 37 | 23 | 24 | Upgrade |
EBT Excluding Unusual Items | 322 | 137 | 37 | 300 | 452 | 207 | Upgrade |
Gain (Loss) on Sale of Investments | 16 | 16 | 16 | - | - | -1 | Upgrade |
Gain (Loss) on Sale of Assets | 1 | 64 | - | - | - | - | Upgrade |
Asset Writedown | - | - | -1 | -2 | -9 | - | Upgrade |
Other Unusual Items | -57 | - | 1 | - | - | - | Upgrade |
Pretax Income | 282 | 217 | 53 | 298 | 443 | 206 | Upgrade |
Income Tax Expense | 76 | 51 | 10 | 80 | 120 | 53 | Upgrade |
Earnings From Continuing Operations | 206 | 166 | 43 | 218 | 323 | 153 | Upgrade |
Minority Interest in Earnings | -8 | -34 | -7 | -6 | -10 | -7 | Upgrade |
Net Income | 198 | 132 | 36 | 212 | 313 | 146 | Upgrade |
Net Income to Common | 198 | 132 | 36 | 212 | 313 | 146 | Upgrade |
Net Income Growth | 132.94% | 266.67% | -83.02% | -32.27% | 114.38% | 13.18% | Upgrade |
Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade |
Shares Change (YoY) | -3.61% | -4.00% | -1.35% | -0.02% | -0.02% | -0.01% | Upgrade |
EPS (Basic) | 220.89 | 145.44 | 38.08 | 221.23 | 326.57 | 152.31 | Upgrade |
EPS (Diluted) | 220.89 | 145.44 | 38.08 | 221.23 | 326.57 | 152.31 | Upgrade |
EPS Growth | 141.66% | 281.95% | -82.79% | -32.26% | 114.42% | 13.19% | Upgrade |
Free Cash Flow | 65 | 387 | -462 | -270 | 521 | 239 | Upgrade |
Free Cash Flow Per Share | 72.52 | 426.42 | -488.69 | -281.76 | 543.59 | 249.32 | Upgrade |
Dividend Per Share | 25.000 | 25.000 | 25.000 | 30.000 | 25.000 | 19.000 | Upgrade |
Dividend Growth | - | - | -16.67% | 20.00% | 31.58% | 5.56% | Upgrade |
Gross Margin | 25.50% | 22.60% | 22.22% | 21.68% | 25.88% | 24.11% | Upgrade |
Operating Margin | 4.37% | 0.74% | -0.18% | 3.22% | 5.59% | 2.37% | Upgrade |
Profit Margin | 3.09% | 2.18% | 0.60% | 2.93% | 4.45% | 2.18% | Upgrade |
Free Cash Flow Margin | 1.01% | 6.40% | -7.70% | -3.73% | 7.41% | 3.56% | Upgrade |
EBITDA | 405 | 171 | 107 | 336 | 500 | 269 | Upgrade |
EBITDA Margin | 6.32% | 2.83% | 1.78% | 4.64% | 7.11% | 4.01% | Upgrade |
D&A For EBITDA | 125 | 126 | 118 | 103 | 107 | 110 | Upgrade |
EBIT | 280 | 45 | -11 | 233 | 393 | 159 | Upgrade |
EBIT Margin | 4.37% | 0.74% | -0.18% | 3.22% | 5.59% | 2.37% | Upgrade |
Effective Tax Rate | 26.95% | 23.50% | 18.87% | 26.85% | 27.09% | 25.73% | Upgrade |
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.